ABSTRACT

Invented test-kit to evaluate the Early Warning diagnostic value of combination of Sensitive & Unique Serum CEA, CA125, CA19.9 and CA15.3 detection of Carcinoembryonic Antigen Proteins (CEA), Cancer Antigen 125 (CA125), Carbohydrate Antigen 19.9 (CA19.9) and Cancer Antigen 15.3 (CA15.3) in patients with Breast Cancer, Liver Cancer, Colorectal & Rectal Cancer, Lungs Cancer, Pancreatic Cancer & Ovarian Cancer etc. All by polling the open studies related to combination early warning detection in serum CEA, CA125, CA19.9 and CA15.3 in patients with Breast Cancer, Liver Cancer, Colorectal & Rectal Cancer, Lungs Cancer, Pancreatic Cancer & Ovarian Cancer with clinical studies of True Positive results from Zhuhai Zhen Guo Tumours Recovery Hospital (ROC) report on dated, 28th August 2016 (Ref: Test report). The combination of serum early warning detection of serum diagnostic sensitivity, specificity and accuracy rate is performed and completed in comparison with the laboratory standard CEA, AFP detector using 100 different patients' whole blood or serum. The Sensitivity Positive Rate is 98%, Specificity Rate is 99%, while total Accuracy Rate is 98% (whichever is lesser), respectively by fixed or random effect model. No publication bias was found according to the test.

Figure of Publication

Figure 1